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Three DNA binding polyamides (1–3) were synthe-
sized that bind with high affinity (Ka 5 8.7 z 10
9 M21 to 1.4
z 1010 M21) to two 7-base pair sequences overlapping the
Ets DNA binding site (EBS; GAGGAA) within the regu-
latory region of the HER2/neu proximal promoter. As
measured by electrophoretic mobility shift assay, poly-
amides binding to flanking elements upstream (1) or
downstream (2 and 3) of the EBS were one to two orders
of magnitude more effective than the natural product
distamycin at inhibiting formation of complexes be-
tween the purified EBS protein, epithelial restricted
with serine box (ESX), and the HER2/neu promoter
probe. One polyamide, 2, completely blocked Ets-DNA
complex formation at 10 nM ligand concentration,
whereas formation of activator protein-2-DNA com-
plexes was unaffected at the activator protein-2 binding
site immediately upstream of the HER2/neu EBS, even at
100 nM ligand concentration. At equilibrium, polyamide
1 was equally effective at inhibiting Ets/DNA binding
when added before or after in vitro formation of protein-
promoter complexes, demonstrating its utility to dis-
rupt endogenous Ets-mediated HER2/neu preinitiation
complexes. Polyamide 2, the most potent inhibitor of
Ets-DNA complex formation by electrophoretic mobility
shift assay, was also the most effective inhibitor of
HER2/neu promoter-driven transcription measured in a
cell-free system using nuclear extract from an ESX- and
HER2/neu-overexpressing human breast cancer cell
line, SKBR-3.
Abnormal regulation of gene expression plays an important
role in cancer (1, 2). The first step in the regulation of gene
expression requires transcription factor (TF)1 binding to its
cognate DNA response element in the gene promoter region
(3–5). The ability to preferentially block gene expression by
interfering with TF-DNA complexes could be a powerful tool for
elucidating how aberrant gene expression contributes to neo-
plastic phenotypes.
One strategy for developing gene-specific transcriptional in-
hibitors is to target DNA binding ligands to the cognate DNA
response element of a crucial, promoter-regulating TF (6–8). A
number of DNA binding natural products and their analogs,
which interfere with the binding of TFs to their promoter
response elements, are potent inhibitors of gene expression
(9–14). Mithramycin, a G,C-specific DNA minor groove binder,
inhibits c-Myc expression driven by its G,C-rich P1 promoter
(9, 10). Similarly, small molecules such as the DNA intercala-
tor mitoxantrone and the minor groove binding distamycin
(Dist), both of which can inhibit the binding of E2F1 to the
dihydrofolate reductase promoter, are strong inhibitors of di-
hydrofolate reductase gene expression (11). However, most
DNA binding ligands are not promoter- or TF-specific inhibi-
tors; Dist, for example, is also known to inhibit gene transcrip-
tion by interfering with the association of TATA box-binding
protein to its A,T-rich response element (TATA box) found in
the proximal promoter of many genes (12).
We have been investigating a new class of DNA minor groove
binding ligands, hairpin pyrrole-imidazole polyamides, as po-
tential promoter- and TF-specific inhibitors of gene expression.
In this study we have designed several new polyamides specif-
ically targeted to the Ets binding site (EBS) within the proxi-
mal promoter of the HER2/neu oncogene. Hairpin polyamides
represent a significant advancement in ligand design in that
they can achieve a remarkable degree of sequence specificity
and high affinity for predetermined DNA sequences (13–15).
Polyamides that contain the aromatic rings N-methylimidazole
(Im) and N-methylpyrrole (Py) bind as pairs in an antiparallel
fashion to specifically distinguish GzC (Im/Py) from CzG (Py/
Im). Py/Py pairs are partially degenerate and bind both AzT
and TzA pairs. More than five aromatic rings are overwound
relative to the DNA helix, and a b-alanine unit has proven to be
a conformationally flexible analog of a pyrrole carboxamide
unit (15). A b/b pair can replace a Py/Py pair and allow for
recognition of longer sequences while maintaining the specific-
ity for AT/TA base pairs (15). Recently, polyamides designed to
interfere with TFIIIA binding to its promoter-response ele-
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ment, were shown to be potent and specific inhibitors of 5 S
RNA gene transcription (16, 17). Such designed polyamides
have also been shown to specifically inhibit the replication of
human immunodeficiency virus, type I virus within the genome
of human blood cells (18).
The HER2/neu oncogene is amplified and transcriptionally
up-regulated in 25–30% of human breast cancers (19). The
dramatic loss of ErbB2/HER2 promoter activity in overexpress-
ing (MDA-453) and normal expressing (MCF-7) cells when a
mutation of the ErbB2/HER2 promoter’s EBS is introduced
(GAGGAA to GAGAGA) into a transfected ErbB2 promoter-
chloramphenicol acetyltransferase reporter construct demon-
strates that the transcriptional up-regulation of HER2/neu de-
pends on a highly conserved EBS and its GAGGAA core
recognition sequence within the key regulatory region of the
HER2/neu proximal promoter (20). Recent studies have con-
firmed, both in vitro and in vivo, that ErbB2-mediated tumor-
igenesis could be inhibited by transfecting an Ets repressor
that binds specifically and uniquely to the same ErbB2/HER2
promoter’s EBS being targeted by our polyamide ligands (21). A
number of polyamides were designed to target the EBS and
adjacent upstream or downstream flanking sequences unique
to this promoter. Three different hairpin polyamides ImPy-b-
PyIm-(R)H2Ng-PyPy-b-ImPy-b-Dp (1), ImPyPyPyPy-(R)H2Ng-
PyPyPyPy-b-Dp (2), and ImPy-b-PyPy-(R)H2Ng-PyPy-b-PyPy-
b-Dp (3) were synthesized to target either the upstream or
downstream EBS flanking sequences 59-TGCTTGA-39 or 59-
AGTATAA-39, respectively (Fig. 1A). Quantitative footprint ti-
tration analysis confirmed their high affinity binding and se-
quence specificity for the HER2/neu EBS. Comparisons were
made between these polyamides and the classical three ring
DNA minor groove binder, Dist, in their abilities to inhibit
binding to the HER2/neu EBS by the mammary gland Ets
factor, ESX, thought to endogenously regulate this promoter in
HER2/neu overexpressing human breast cancers (26). Lastly,
a cell-free transcription assay was used to evaluate the specific
and differential ability of these three polyamides to interfere
with HER2/neu promoter-driven transcription.
MATERIALS AND METHODS
Synthesis of the Polyamides—The polyamides ImPy-b-PyIm-(R)H2Ng-
PyPy-b-ImPy-b-Dp (1), ImPyPyPyPy-(R)H2Ng-PyPyPyPy-b-Dp (2), and
FIG. 1. A, HER2/neu promoter sequence (and TA5 probe) containing Ets (EBS), AP-2, and TATA box-binding protein-response elements, and
showing the 7-bp polyamide binding elements overlapping and positioned just upstream (for polyamide 1) and downstream (for polyamides 2 and
3) of the GAGGAA EBS. Schematic binding model of the polyamides; imidazole and pyrrole rings are represented as shaded and unshaded spheres,
respectively, whereas the b-alanine residues are represented as unshaded diamonds. B, structure of polyamides ImPy-b-PyIm-(R)H2Ng-PyPy-b-
ImPy-b-Dp (1), ImPyPyPyPy-(R)H2Ng-PyPyPyPy-b-Dp (2), and ImPy-b-PyPy-(R)H2Ng-PyPy-b-PyPy-b-Dp (3).
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ImPy-b-PyPy-(R)H2Ng-PyPy-b-PyPy-b-Dp (3) were synthesized from
b-alanine-PAM resin using solid phase as described (22) and was char-
acterized by a combination of analytical high pressure liquid chroma-
tography, UV spectroscopy, and matrix-assisted laser desorption ioni-
zation/time of flight mass spectroscopy. MS, m/z observed for 1, 1380.7;
1380.7 calculated for [M 1 H]1; m/z observed for 2, 1480.6, 1480.7
calculated for [M 1 H]1; m/z observed for 3, 1378.6, 1378.7 calculated for
[M 1 H]1. UV in M21 cm21, for 1, 42,500 (e242), 539100 (e298); for 2,
58,300 (e246), 799600 (e316); for 3, 50,000 (e240), 539600 (e298).
Quantitative DNase I Footprint Titrations—A 188-base pair (bp)
DNA fragment was obtained by polymerase chain reaction using the
plasmid RO6 as a template and the primers P1 (59-GAGAAAGT-
GAAGCTGGGAGTT-39) and P2 (59-CCTGGTTTCTCCGGTCCCAAT-
39). The primer P2 was 59-radiolabeled with [g-32P]ATP using T4-
polynucleotide kinase (Roche Molecular Biochemicals). Polymerase
chain reaction amplification in the presence of P1, P2 (labeled), plasmid
RO6, and Taq polymerase (Roche Molecular Biochemicals) gave a
188-bp DNA fragment that was purified on a 6% nondenaturating
polyacrylamide gel. All DNase I footprint reactions were performed in a
total volume of 400 ml containing a 59-32P-radiolabeled DNA fragment
(17,000 cpm) and final concentrations of 10 mM TriszHCl, 10 mM KCl, 10
mM MgCl2, 5 mM CaCl2, pH 7.0, and either 0.1–10 nM polyamide or no
polyamide (control lanes) (23). The solutions were allowed to equilibrate
for 12–14 h at 22 °C. The footprinting reactions were initiated by the
addition of 10 ml of a stock solution of DNase I containing 1 mM
dithiothreitol and incubated for 7 min at 22 °C. The reactions were
stopped by adding 50 ml of a solution of 2.25 M NaCl, 150 mM EDTA, 28
mM base pair calf thymus DNA, and 0.6 mg/ml glycogen and ethanol
precipitation. The precipitates were resuspended in 13 Tris borate-
EDTA, 80% formamide loading buffer, denaturated by heating at 85 °C
for 10 min, and cooled on ice. The reaction products were separated by
electrophoresis on a 6% polyacrylamide gel in 13 Tris borate-EDTA at
2000 V for 1 h. Gels were dried on a slab dryer and exposed to a
photostimulatable storage phosphorimaging plate (Kodak Storage
Phosphor Screen SO230 obtained from Molecular Dynamics) in the
dark at 22 °C for 12–24 h. The data from the storage screens were
obtained using a Molecular Dynamics 400S PhosphorImager and ana-
lyzed by volume integration of the target sites and reference blocks
using the ImageQuant version 3.3. software. Equilibrium association
constants were determined as described previously (24). Each com-
pound was tested three times; the values for the equilibrium association
constants (Ka) correspond to average values from three independent
gels.
Cell Culture and Nuclear Extract Preparation—SKBR-3 cells were
purchased from ATCC (Rockville, MD) and maintained at 37 °C with
5% CO2 and in McCoy’s 5a medium (Life Technologies, Inc.) with 10%
fetal bovine serum. SKBR-3 cells grown to subconfluence were rinsed
twice with phosphate-buffered saline, scraped, and collected by centrif-
ugation at 1200 rpm for 5 min, 4 °C (Sorvall RT6000, Newtown, CT).
The following steps were performed at 4 °C. Cell pellets were suspended
in five times the packed cell volume in buffer A (containing 10 mM
Hepes-KOH, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.75 mM
spermidine, 0.15 mM spermine, and 1 mM dithiothreitol), followed by
centrifugation at 1200 rpm for 5 min. The pellet was then resuspended
in five times the pellet volume in buffer A, kept on ice for 8 min, and
homogenized with 10 strokes using a Dounce homogenizer (tight pes-
tle). The homogenate (;95% lysed cells) was centrifuged at 15,000 rpm
for ;1 min, (JA-17 rotor, JA-21 centrifuge; Beckman, Palo Alto, CA).
The pellet was resuspended in buffer B with 20 mM Hepes-KOH (pH
7.9), 20% glycerol, 0.2 mM EDTA, 2.0 mM EGTA, 0.75 mM spermidine,
0.15 mM spermine, 2 mM dithiothreitol, and 1 mM phenylmethylsulfonyl
fluoride followed by drop addition of an equal volume of buffer B that
included 0.75 M NaCl. After rocking for 20 min, the supernatant was
collected by centrifugation at 47,500 rpm for 45 min (SW-55 rotor,
Beckman), and dialyzed against .100-fold buffer C (20 mM Hepes-
KOH, pH 7.9, 20% glycerol, 100 mM KCl, 0.2 mM EDTA, 0.2 mM EGTA,
12.5 mM MgCl2, 2 mM dithiothreitol, and 1 mM phenylmethylsulfonyl
fluoride) for 3 h. Precipitated debris was removed by centrifugation at
15,000 rpm (JA-21 centrifuge, JA-17 rotor, Beckman), and the protein
content of the nuclear extract was quantitated using the Bio-Rad pro-
tein assay.
Proteins, Antibodies, and Oligonucleotides—Recombinant ESX pro-
tein was prepared as described (25). Briefly, full-length ESX cDNA was
cloned into a pRSET His tag expression plasmid (NheI-HindIII; Invitro-
gen) and expressed in isopropyl-1-thio-b-D-galactopyranoside-induced
BL21[DE3] pLysS competent bacteria (Stratagene, La Jolla, CA). His-
FIG. 2. Quantitative DNase I footprint titration experiment with the polyamides 1, 2, and 3 on a 5*-32P-radiolabeled, 188-base pair
DNA fragment obtained by polymerase chain reaction from the plasmid RO6. Lane 1, A reaction; lane 2, DNase I standard; lanes 3–12,
10 pM, 20 pM, 50 pM, 100 pM, 200 pM, 500 pM, 1 nM, 2 nM, 5 nM, and 10 nM polyamide; lane 13, intact DNA. All reactions contain a 17-kcpm DNA
fragment, 10 mM TriszHCl (pH 7.0), 10 mM KCl, 10 mM MgCl2, and 5 mM CaCl2.
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tagged ESX protein was purified by Ni21-chelate affinity chromatogra-
phy, as recommended by the manufacturer (Qiagen Inc., Valencia, CA).
Recombinant AP-2 protein was purchased from Promega Co. (Madison,
WI). Monoclonal antibody against AP-2 was purchased from Santa Cruz
Biochemical (Carpenteria, CA), and the anti-ESX affinity-purified rab-
bit polyclonal was prepared as described previously (26). A 34-mer DNA
oligonucleotide (oligo) containing the EBS and derived from the HER2/
neu proximal promoter (TA5 sequence shown in Fig. 1A) and its com-
plementary strand, were synthesized by the Biopolymers facility
(Roswell Park Cancer Institute, Buffalo, NY). Oligos were gel-purified,
annealed, and 59-end-labeled with [g-32P]ATP using T4-polynucleotide
kinase (New England BioLabs, Beverly, MA) as described previously
(27).
Mobility Shift Assay—Demonstration of TFs binding to their DNA
response elements in the proximal HER2/neu promoter was performed
by EMSA using recombinant TFs (ESX, AP-2), duplexed and 59-end-
labeled TA5 promoter probe, with/without anti-TF antibody. In general,
recombinant protein at the indicated concentrations and 1 nM 32P-
labeled DNA probe were incubated in a reaction buffer containing 25
mM Tris (pH 7.5), 30 mM KCl, 5% glycerol, 0.1% Nonidet P-40, bovine
serum albumin (100 mg/ml), and 1 mM dithiothreitol. After incubation
at room temperature for 30 min, samples were loaded onto 5% native
polyacrylamide gels running with Tris borate-EDTA buffer (44.5 mM
Tris base, 44.5 mM boric acid, 1 mM EDTA, pH 8.3). The dried gel was
exposed to Kodak film and the protein-DNA complexes were quanti-
tated by computing laser densitometry (Molecular Dynamics, Sunny-
vale, CA).
Identification of specific protein-DNA complexes was confirmed by
the addition of specific antibodies in the EMSA reaction conditions, as
indicated. The ability of polyamides to interfere with the formation of a
protein-DNA complex was determined by EMSA. For polyamide effects
FIG. 3. EMSA comparison of polyamide 2 versus Dist inhibition of ESX-TA5 complex formation. A, EMSA performed in the presence
of 2 was used to evaluate the ability of polyamides to inhibit ESX binding to the labeled TA5 HER2/neu promoter probe. As described under
“Materials and Methods,” labeled TA5 probe and compound were incubated for 30 min at room temperature followed by the addition of ESX and
subsequent a 30-min incubation. Complexes formed in solution were then separated on a 5% native polyacrylamide gel and visualized by
autoradiography. Lane 1, control of ESX-TA5; lanes 2–6, samples in the presence of 2 at concentrations of 100, 10, 1, 0.5, and 0.1 nM, respectively;
lane 7, control of free TA5 probe. B, EMSA performed in the presence of Dist under the same assay conditions as described for 2. Lane 1, control
of ESX-TA5; lanes 2–6, samples in the presence of Dist at indicated concentration of 10, 5, 2, 1, and 0.1 mM, respectively; lane 7, control of free probe.
C, inhibition of ESX-TA5 complex formation in the presence of 2 or Dist, plotted as the percentage of control ESX-TA5 complex formation. 2 (l )
and Dist () at the indicated concentrations were incubated with the TA5 probe prior to the addition of recombinant ESX protein. The densitometry
quantitated data represent the mean values (6 S.D.) from at least three separate experiments.
FIG. 4. Inhibition of ESX-TA5 complex formation after pre-
treatment of HER2/neu promoter probe with various poly-
amides. EMSA experiments were performed as described in Fig. 3A.
Radiolabeled TA5 probe and polyamides 1 (l ), 2 (), or 3 (f) were
incubated for 30 min at room temperature before the addition of recom-
binant ESX protein. Following gel separation, autoradiography, and
densitometry, data are represented as mean values (6 S.D.) from three
separate experiments.
TABLE I
Effects on TF-DNA complex formation by polyamides
Polyamide TF IC50 IC50 r value
a
nM
1 ESX 5 0.16
AP-2 48 1.55
2 ESX 2.2 0.07
AP-2 .100 ndb
3 ESX 18 0.58
AP-2 nd nd
Dist ESX 500 16.1
AP-2 6000 193.5
a r value, the molar ratio of compound to DNA base pairs.
b nd, not determined.
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on monomeric ESX binding to TA5 (ESX-TA5 complex formation), as-
says were performed in two ways: (i) polyamides were incubated with a
32P-labeled probe at room temperature for 30 min prior to the addition
of ESX protein, and (ii) ESX protein was complexed with the probe prior
to polyamide treatment. The inhibition of ESX-TA5 complex formation
was measured by comparing polyamide-treated with nontreated sam-
ples. Polyamide ability to inhibit dimeric AP-2 binding to TA5 (AP-2-
TA5 complex formation) was measured in a similar manner. IC50 values
(concentration of compound required for 50% inhibition of protein-DNA
complex formation) were determined to express the inhibitory activity
of each agent; these IC50 polyamide concentrations were also expressed
as r values, the molar ratio of ligand to DNA base pairs.
Cell-free Transcription Assay—In vitro transcription was performed
in a cell-free system composed of DNA template, SKBR-3 nuclear ex-
tract, and buffer containing 12 mM Hepes-KOH (pH 7.9), 60 mM KCl, 7.5
mM MgCl2, 12% glycerol, 0.12 mM EDTA, 0.12 mM EGTA, 1.2 mM
dithiothreitol, and 0.6 mM phenylmethylsulfonyl fluoride. The tran-
scription DNA template consisted of CsCl-purified plasmid DNA con-
taining the ;500-bp RO6 HER2/neu promoter fragment (20), inserted
into a pCDNA3-Luc expression vector (Invitrogen, Carlsbad, CA), and
linearized by restriction with SphI (New England BioLabs, Beverly,
MA). Into a 25-ml reaction of SKBR-3 nuclear extract was added 1 mg of
SphI-digested DNA, nuclear extracts, 0.5 ml of each nucleotide (20 mM
of ATP, GTP, UTP, and 100 mM CTP), 10 mCi of [a-32P]CTP (800
Ci/mmole; NEN Life Science Products), 1 ml of RNAsin (40 units/ml;
Roche Molecular Biochemicals), and 1.4 ml of EDTA (2.5 mM). Tran-
script formation proceeded with incubation at 30 °C for 60 min, and the
reaction was stopped by adding 325 ml of 10 mM Tris base (pH 8.0), 7 M
urea, 350 mM NaCl, 1% SDS, and 100 mg of tRNA, followed by phenol-
chloroform-isoamyl alcohol extraction and ethanol precipitation. Sam-
ples were resuspended in formamide-loading dye and heated at 90–
95 °C for $1 min before loading onto a 4%, 7 M urea-polyacrylamide gel.
The 32P signal from a dried gel was visualized using a PhosphorImager
screen and quantitated by computing laser densitometry (Molecular
Dynamics, Sunnyvale, CA).
As with EMSA assessment of polyamide activity, ligand ability to
inhibit transcript formation driven off the HER2/neu promoter was
analyzed in two ways: (i) DNA template was incubated with polyamide
at the indicated concentration in a total volume of 10 ml for 30 min prior
to the addition of nuclear extract and radiolabeled nucleotide pool, and
(ii) preincubation of nuclear extract and DNA template for 15 min was
followed by the addition of ligand for another 30 min in the total
reaction volume to which radiolabeled nucleotide pool was then added.
The degree of transcription was measured by quantitating transcript
formation in ligand-treated versus untreated (control) samples and
calculating IC50 and r values. T3 transcript (250 bases; Promega Co.,
Madison, WI) was used as an internal control. In addition, a time course
assay was used to compare transcriptional inhibition off the HER2/neu
promoter in the presence of Dist versus polyamide 2 using our previ-
ously described procedure (11). For these time course assays, following
the addition of ligands and nucleotides to the premixed template and
nuclear extract volume, the reaction was stopped at different time
points (0–60 min), and the newly formed transcripts were quantitated
as described above.
RESULTS
Design of HER2/neu Promoter Binding Polyamides—We
used the simple pairing code (15) to design polyamides that
bind the 59- and 39-flanking sequences overlapping the EBS
(GAGGAA) within the endogenous HER2/neu proximal pro-
moter, the RO6 HER2/neu promoter-driven transcript tem-
plate, and the EMSA TA5 probe. The proximal HER2/neu pro-
moter sequence containing this EBS is shown in Fig. 1A, and
this HER2/neu EBS has previously been shown to bind with
high affinity to the potent and epithelial-restricted Ets trans-
activator, ESX (25, 26). All Ets family members bind to the
major groove of DNA and have additional critical phosphate
contacts along flanking minor groove sequences (28, 29).
Whereas the GGAA core of the EBS is the same for virtually all
Ets proteins, these 59- and 39-sequences immediately adjacent
to the EBS core are often promoter- and Ets factor-specific.
Thus, we synthesized three polyamides to target 7 bp of the
HER2/neu promoter sequence 59 and 39 of the EBS core; poly-
amide 1 was designed to bind immediately upstream of the
ESX core binding site at 59-TGCTTGA-39 (site 1), whereas
polyamides 2 and 3 were designed to bind immediately down-
stream and across the adjacent TATA box at 59-AGTATAA-39
(site 2).
Selectivity and High Affinity Binding of Polyamides to the
HER2/neu Promoter EBS—Quantitative DNase I footprint ti-
tration analysis showed that polyamides 1, 2, and 3 bind with
high affinity to their target sites (Fig. 2). Polyamide 1 binds
with an equilibrium association constant Ka 5 9.6 z 10
9 M21 to
its match site (59-TGCTTGA-39). It binds by a factor of ;2 less
strongly to a single base pair mismatch site (59-AGAATGA-39)
located downstream with respect to the ESX binding site (Ka 5
4.5 z 109 M21). Polyamides 2 and 3 both bind with high affinity
FIG. 5. Comparative HER2/neu inhibitory effects of poly-
amides administered before or after formation of ESX-TA5 com-
plexes. EMSA performed when 1 (A) or 2 (B) were added at indicated
concentrations either before (f) or after (l) formation of ESX-TA5
complexes. Following gel separation, autoradiography, and densitome-
try, data are represented as mean values (6 S.D.) from at least three
separate experiments. A time course assay was used to estimate the
time required for 2 to reach steady-state equilibrium in terms of inhi-
bition of ESX-TA5 complex formation (C). ESX and radiolabeled TA5
probe were incubated at room temperature for 30 min followed by the
addition of polyamide 2 at 10 mM for 240, 120, 60, 30, or 15 min;
replicate assay results are expressed as mean values (6 S.D.).
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to their target site (59-AGTATAA-39, Ka 5 1.4 z 10
10 M21 and Ka
5 8.7 z 109 M21, respectively).
Polyamide 2 Inhibition of Ets Binding to the HER2/neu
Promoter—Because Dist can also bind to the TATA box con-
tained in the 39-EBS element targeted by two of the polyamides
(12), polyamide 2 and Dist were compared by EMSA for their
abilities to inhibit ESX binding to the HER2/neu promoter
probe, TA5. Incubation of 2 with TA5 followed by the addition
of ESX resulted in a concentration-dependent inhibition of
ESX-TA5 complex formation; 10 nM 2 inhibited complex forma-
tion up to 95%, whereas as little as 1 nM resulted in a detectable
decrease in complex formation (Fig. 3A, lanes 2–4). The pattern
of inhibition of ESX-TA5 complex formation by Dist was simi-
lar, but significantly higher Dist concentration was required to
achieve the same degree of inhibition observed by 2, because
Dist at 2000 nM diminished complex formation by ;95% (Fig.
3B, lane 4). Whereas 100 nM of 2 inhibited ESX-TA5 complex
formation almost entirely, 100 nM Dist had no effect on ESX-
TA5 complex formation (Fig. 3A, lane 2 and Fig. 3B, lane 6).
Quantitation of the data in Fig. 3C indicated that 2.2 nM 2 and
500 nM Dist are needed to inhibit complex formation by 50%
(IC50); Table I also shows the activity of individual polyamides
at inhibiting protein-DNA complex formation expressed as r
values, the molar ratio of ligand to DNA base pairs.
Inhibitory Effects of Polyamides (1, 2, and 3) on Ets Binding
to the HER2/neu Promoter—Because 1 and 2 recognize DNA
elements upstream and downstream of the core EBS while 3
also recognizes the same downstream flanking element as 2
(Fig. 1), EMSA was used to test the relative ability of each
polyamide to inhibit ESX binding to the HER2/neu promoter
probe TA5. As shown in Fig. 4, 1 and 2 appeared similar in
their ability to inhibit complex formation with respective IC50
values of 5 and 2.2 nM. In contrast, 3 required a 9-fold higher
concentration (18 nM) to prevent Ets-DNA complex formation
by 50% as compared with 2 (Fig. 4 and Table I).
For certain TF/DNA inhibitory drugs, equilibrium conditions
demand greater drug concentrations to inhibit preformed
DNA-bound complexes as opposed to preventing the initial
formation of such complexes (6). For polyamide 1, however,
similar experimental conditions were observed for inhibition of
Ets-DNA complexes whether ligand was added before or after
ESX binding to the HER2/neu promoter probe, because at 10
nM polyamide 1 concentration nearly the same level of ESX-
TA5 complexes were formed within 30 min no matter which
order the reagents were added (Fig. 5A). In contrast, 2 required
10-fold more ligand to obtain equal inhibition when added after
ESX-TA5 complex formation as compared with the addition of
2 before complex formation (Fig. 5B). A time course assay using
10 nM of 2 indicated that the percentage of ESX-TA5 complexes
inhibited by 2 increased with longer incubation time such that
a $4 h polyamide 2 incubation was needed to achieve equilib-
rium conditions and maximal inhibition when 2 was added
after the initial formation of ESX-TA5 complexes (Fig. 5C).
Inhibitory Effects of Polyamides on AP-2 Versus Ets Binding
to the HER2/neu Promoter—Previous studies have suggested
that AP-2 contributes to the overexpression of HER2/neu, and
footprinting analysis has revealed that there are several AP-2
sites in the proximal HER2/neu promoter (30). We also had
observed that both endogenous and recombinant AP-2 binds to
a G-rich sequence just upstream of the EBS on the HER2/neu
promoter. Dimeric binding of AP-2 to this G-rich element in the
TA5 probe (Fig. 1) is demonstrable by EMSA and confirmed by
the supershifting effect of an AP-2 monoclonal; in contrast,
antibodies nonreactive to AP-2 had no effect on this AP-2-TA5
complex (Fig. 6A). Because AP-2 interacts with this G-rich
element adjacent to the EBS in TA5, it was of interest to know
whether the EBS-targeted polyamides would affect the binding
of AP-2 to this HER2/neu promoter probe. Fig. 6B shows that 1
FIG. 6. Antibody-specific AP-2 binding to the HER2/neu promoter probe TA5, and polyamide versus Dist inhibition of AP-2-TA5
complex formation. Demonstration of specific AP-2 binding to TA5 confirmed by AP-2 antibody-induced supershifting on EMSA. Recombinant
AP-2 protein with/without monoclonal antibodies were incubated for 10 min prior to the addition of radiolabeled TA5 probe, as described under
“Materials and Methods.” A, lane 1, control of free TA5 probe; lane 2, AP-2-TA5 complexes; lanes 3–5, reactions with antibodies of A (AP-2), S (Sp1),
and N (normal immunoglobulins), showing formation of a slower migrating (supershifted) TA5 complex only in the presence of AP-2-TA5 binding
monoclonal. Inhibition of the AP-2-TA5 complexes () was compared with EMSA formation of ESX-TA5 complexes ( l ) in the presence of (B) 1, (C)
2, or (D) Dist. All results are expressed as mean values (6 S.D.) from replicate experiments each performed with duplicate samples.
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was capable of inhibiting EMSA-detected AP-2-TA5 complexes
in a concentration-dependent manner and with an IC50 5 48
nM. In contrast, 2 was unable to block complex formation even
at the highest concentration (100 nM) tested (Fig. 6C).2 Like-
wise, the pattern of inhibition of AP-2-TA5 complexes by Dist
was similar to that of 2 in that micromolar concentrations were
required to significantly inhibit complex formation (Fig. 6D and
Table I). All these compounds were more efficient at inhibiting
formation of ESX (versus AP-2) complexes on the HER2/neu
promoter probe, with 2 being the most specific and most potent
inhibitor.
Transcription Inhibiting Effects of Polyamides on the HER2/
neu Promoter—To determine whether the effects of polyamides
on Ets-DNA complex formation resulted in an ability to influ-
ence biological function, in vitro transcription assays were per-
formed using a HER2/neu promoter-driven DNA template.
With the ;500 bp of HER2/neu promoter-inserted plasmid
(RO6) linearized with SphI as DNA template and SKBR-3
nuclear extracts (endogenously enriched in ESX, AP-2, TATA
box-binding protein, etc.) to provide the transcriptional ma-
chinery, a ;760-base transcript is produced in this cell-free
system. Compounds were first incubated with the DNA tem-
plate prior to the addition of nuclear extracts and radiolabeled
pool of nucleotides. A representative gel shown in Fig. 7A
demonstrates the ability of 2 to block synthesis of the 760-base
transcript in a concentration-dependent manner. Compared
with the untreated control, 5 mM of 2 inhibited transcript syn-
thesis by 95%; whereas 1 mM produced less than 50% inhibition
of transcript formation, at higher polyamide concentrations
there was some evidence of the partial transcript production
(Fig. 7A, lanes 3 and 4). Comparative inhibition of HER2/neu
promoter-driven transcription by 1, 2, 3, and Dist is shown in
Fig. 7B. The order of transcription inhibiting potency (2 . 3 .
1 . Dist) is somewhat different from the EMSA ESX-TA5
complex inhibiting potency for these compounds. Their corre-
sponding IC50 values are 1.4 mM for 2, 2.4 mM for 3, 3.2 mM for
1, and 7.4 mM for Dist; their r values are also shown in Table II.
Because EMSA results demonstrated differences between
the ability of 1 and 2 to inhibit Ets-DNA complexes when
ligand was given before or after initial formation of the ESX-
TA5 complex (Fig. 5), to determine if the order of addition of
polyamides influenced their transcription inhibitory activity,
nuclear extracts were allowed to interact with the promoter
and DNA template prior to ligand exposure. Polyamide effec-
tiveness appeared to be reduced when tested in this fashion
(Fig. 8). For example, concentrations of 2 at 1.4 or 4.2 mM were
required to inhibit transcription by 50% when ligand was
added before or after nuclear extract binding with the R06
template (Fig. 8A). In the case of 1, a 2-fold higher ligand
concentration was needed to inhibit transcription (6.4 mM)
when extract was prebound to template (Fig. 8B).
Previous time course studies with DNA binding and tran-
scription-inhibiting drugs have shown that the degree of tran-
scription inhibition can change in relation to the in vitro reac-
tion time in the presence of moderately inhibiting drug
concentrations (11). Conducting similar time course experi-
ments with the most potent inhibitor 2 revealed a plateau level
of transcription inhibition at all time points from 10–60 min
(Fig. 9). In contrast, the level of transcription inhibition by Dist
declined somewhat in relation to incubation time. These time
course differences between 2 and Dist might be accounted for
by the higher DNA binding affinity of the polyamide, making it
less likely that ligand is released from the template and tran-
scription is allowed to resume during the longer exposure
times.
2 Polyamide concentration greater than 100 nM caused smearing of
the DNA under our assay conditions.
FIG. 7. Polyamide and Dist pretreatment of the HER2/neu pro-
moter inhibits its transcriptional activity. HER2/neu promoter-
driven transcription was measured in a cell-free assay as described
under “Materials and Methods”; briefly, compound at the indicated
concentration was incubated with a SphI-restricted HER2/neu promot-
er-driven transcription template (RO6) at 30 °C for 30 min, followed by
the addition of SKBR-3 nuclear extract and a radiolabeled pool of
nucleotide precursors. Transcription was allowed to proceed for 60 min
at 30 °C with the expected ;760-base transcript identified by gel elec-
trophoretic separation and phosphorimaging of the scanned gel. Scan
from a representative experiment performed in the presence of polyam-
ide 2 is shown in A. Lane 1, untreated control; lanes 2–4, cell-free
transcription performed in the presence of 1, 2.5, and 5 mM 2; lane 5,
RNA marker. IC, internal control; TC, 760-base transcript. Activities of
polyamides, 1 (l ), 2 (), 3 (f), and Dist (l) are presented as percentage
inhibition of transcript formation comparing the compound-treated con-
dition with untreated control (B) and transcript formation in individual
samples normalized to the internal control. Results represent the mean
values (6 S.D.) of replicate experiments.
TABLE II
Effects on the in vitro transcription by polyamides
Polyamide IC50 IC50 r value
mM
1 3.2 0.02
2 1.4 0.009
3 2.4 0.015
Dist 7.4 0.05
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DISCUSSION
In this study, we examined the ability of sequence-specific
polyamides to inhibit Ets-DNA complex formation and EBS-
regulated transcription off the HER2/neu promoter. Poly-
amides were synthesized that recognize different elements
overlapping and flanking the GAGGAA EBS, located adjacent
to and 59 of the TATA-box in the regulatory portion of the
proximal HER2/neu promoter (20). As compared with the
TATA box binding natural product Dist, three designed se-
quence-specific polyamides were more effective at inhibiting
EBS complex formation with the mammary gland Ets transac-
tivator, ESX, as well as HER2/neu driven transcription from a
;500 bp HER2/neu promoter sequence known to be regulated
at the EBS as well as other endogenous response elements (e.g.
AP-2, Sp1, CAAT, and TATA boxes). Of the three polyamides, 2
was the most strongly binding and effective HER2/neu pro-
moter inhibitor, binding with a Ka 5 1.4 z 10
10 M21 to the
39-flanking EBS element that includes the promoter’s TATA
box.
Comparison of the three polyamides (1-3) with Dist for inhi-
bition of protein-DNA complex formation on the HER2/neu
promoter probe, TA5, revealed the vastly enhanced potency
and specificity of the high affinity hairpins as opposed to the
latter natural product. Because both Dist and polyamides 2 and
3 bind the same TATA box containing the 39-EBS element (Fig.
1), the higher binding affinity of 2 for this element likely
contributed to its greater inhibitory activity over both Dist and
polyamide 3. However, because Ets family members also make
minor groove phosphate contacts in addition to their major
groove base contacts, some of the enhanced inhibitory effects of
both these polyamides over Dist may be attributed to steric
effects restricting Ets (ESX) access to the HER2/neu EBS (28,
31). With a similar comparison in the present study, HER2/neu
promoter-targeted polyamides were shown to differentially af-
fect ESX and AP-2 binding to adjacent DNA response elements.
The binding of polyamide 1 to its 59-EBS element partially
impinges on the G-rich AP-2 binding site present in the TA5
probe (Fig. 1), probably accounting for the observed ;10-fold
less effective inhibitory activity of 1 at blocking formation of
AP-2-TA5 versus ESX-TA5 complexes (Fig. 6B). Comparing
Dist and polyamide 2 (Fig. 6, C and D), both of which bind the
same 39-EBS element located more remote from the AP-2 bind-
ing element in TA5, demonstrated the vastly improved pro-
moter specificity of a designed polyamide over a less specific
natural product like Dist, because the latter showed some AP-2
inhibitory activity whereas the former showed none despite its
potent ESX-TA5 inhibitory activity over the same concentra-
tion range.
Small molecules that bind DNA near or at a TF response
element typically require more time (or higher concentrations)
to achieve steady-state inhibition of protein-DNA complexes
when added after rather than before the formation of these
complexes (6, 12, 27). Differences in this regard were noted
between polyamides 1 and 2 when EMSA was carried out with
ligands added before or 30 min after formation of ESX-TA5
complexes; polyamide 1 showed no significant impact by de-
layed administration but 2 showed a near 50% increase in its
IC50 (Fig. 5, A and B). However, by increasing its post-treat-
ment incubation time from 30 min to 240 min, a 10 nM dose of
polyamide 2 regained its full inhibitory activity as seen with a
30-min pretreatment at this same dose (Fig. 5C), demonstrat-
ing that 2 required longer post-treatment exposure than 1 to
achieve its steady-state inhibitory potential. The difference in
FIG. 8. Comparative inhibition of HER2/neu promoter-driven transcription when polyamides are administered before or after
promoter binding to endogenous transcription factors contained in SKBR-3 nuclear extract. The experimental procedure was similar
to that described in Fig. 7A except that the promoter-driven DNA template was incubated with SKBR-3 nuclear extracts for 15 min before the
addition of a labeled pool of nucleotide precursors and polyamides 2 (A) or 1 (B). The percent inhibition of transcript formation () produced by the
individual ligands was compared with that produced when ligand exposure to template preceded the addition of nuclear extract ( l ). Results
represent the mean (6 S.D.) of replicate experiments.
FIG. 9. Inhibition of HER2/neu promoter-driven transcription
when compound is administered after template binding to nu-
clear extract and as a function of exposure time. The experimen-
tal procedure was similar to that described in Fig. 8 except that the
cell-free transcription reaction was stopped after a 5-, 10-, 30-, or
60-min exposure to 2 (l ) and Dist (). Results represent the mean (6
S.D.) of replicate experiments.
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this regard between polyamides 1 and 2 likely reflects 39-
versus 59-asymmetry in the TA5-bound ESX complex, resulting
in greater structural interference and reduced access to the
TA5 element recognized by 2 in the presence of preformed
ESX-TA5 complexes (Fig. 9).
Polyamide 2, which most effectively inhibited ESX-TA5 com-
plex formation at equilibrium also most effectively inhibited
HER2/neu promoter-driven transcription, assayed in a cell-free
system utilizing endogenous ESX, AP-2, TATA box-binding
protein, and other transcriptional components endogenously
present in a nuclear extract of the HER2/neu overexpressing
breast cancer cell line, SKBR-3. Interestingly, polyamide 3,
which was 3-fold less inhibitory than 1 at inhibiting formation
of ESX-TA5 complexes on the 34-bp TA5 promoter probe (IC50
of 18 nM versus 5 nM), was at least as effective as 1 at inhibiting
cell-free transcription off the ;500-bp (R06) HER2/neu promot-
er-driven template. Moreover, the inhibitory activity of poly-
amide 1, which was unaffected in EMSA by prebinding of ESX
to TA5, was moderately reduced in the cell-free transcription
assay by prebinding of nuclear extract to the HER2/neu pro-
moter-driven template, as was the transcription inhibitory ac-
tivity of polyamide 2. Similar discordances were observed in
comparisons of mitoxantrone and Dist as inhibitors of both
protein-DNA complex formation and cell-free transcription
with the DHFR promoter (11). Possible variables accounting
for these discordances in the present study include the multi-
plicity of endogenous HER2/neu promoter binding factors pres-
ent in the nuclear extract fueling the transcription assay (ver-
sus the single protein component in the EMSA assay) and
potentially different numbers of lower affinity binding sites for
each polyamide on the linearized R06 plasmid-containing
HER2/neu promoter-driven template (versus the 34-bp TA5
EMSA probe). To address the potential impact of DNA content
(bp) as a discordance-inducing variable between the EMSA and
cell-free transcription assay, r values were calculated to com-
pare the molar ratios of polyamide to DNA content (Tables I,
and II). The degree of difference between the EMSA and tran-
scription assay r values for Dist is most notable and without
obvious explanation. However, the lower overall r values
among polyamides tested by transcription assay versus their
EMSA determined values suggest that differences in total DNA
content or polyamide binding sites on the HER2/neu promoter-
containing plasmid template did not substantially contribute to
the discordances noted above.
In summary, polyamides designed to selectively target crit-
ical 7-bp elements flanking and overlapping on a singular EBS
in the regulatory region of the proximal HER2/neu promoter
were shown to exhibit high affinity binding to their respective
elements and to specifically disrupt binding of a HER2/neu
promoter EBS candidate, ESX. These Ets-DNA complex inhib-
iting hairpin polyamides were significantly more potent inhib-
itors of HER2/neu promoter-driven transcription than the nat-
ural product Dist, a TATA box minor groove binder, and less
effective Ets-DNA complex inhibitor. The differences noted in
the HER2/neu promoter inhibiting activities of these poly-
amides is thought to be because of both their respective binding
affinities and the choice of EBS flanking elements targeted for
polyamide binding. These differences may implicate vulnerable
promoter elements for future attempts to repress transcription
of the overexpressing HER2/neu oncogene. Studies are now
underway to evaluate the effectiveness of polyamides as HER2/
neu transcription inhibitors in whole cell systems.
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